Treatment of acute febrile neutrophilic dermatosis (Sweet's syndrome) with colchicine

S. Suehisa,H. Tagami

DOI: https://doi.org/10.1111/j.1365-2133.1981.tb00785.x

IF: 11.113

1981-10-01

British Journal of Dermatology

Abstract:SIR, We recently saw a patient with Sweet's syndrome, who showed a very rapid improvement with colchicine. The patient was a 29-year-old man with a 5-day history of dusky-red, tender, swollen plaques on the left forehead and the right upper eyelid associated with aphthous stomatitis. Five months previously he had suffered from similar tender red plaques on the face with severe arthralgia involving the hip and knee joints, oral aphthae and neutrophilic leukocytosis. The diagnosis of Sweet's disease was made on the basis of the clinical and histopathological features of the skin lesions. At that time he did not respond to oral potassium iodide 0-5 mg three times daily for 5 days (Horio et al., 1980) but he gradually improved with oral prednisone 10 mg daily for 4 weeks. On this occasion he was treated with 05 mg of oral colchicine three times daily. Within 2 days the tender erythematous plaques and aphthae began to recede and they disappeared within i week without the development of arthralgia. Since Sweet's syndrome shows massive polymorphonuclear leukocyte (PMN) infiltration in the dermis with increased chemotactic activity of the peripheral blood PMNs in the acute stage (Oseroff eta/., 1981), we surmise that colchicine acted as it does in Beh9et's disease and other diseases in which PMNs play a crucial role (Matsumura & Mizushima, 1975; Hanzen & Michel, 1979). Colchicine is known to inhibit the chemotaxis of PMNs and it decreases leukocyte motility in t)Uro, blocks leukocyte adhesiveness, and stabilizes lysosomal membranes. In our case colchicine seemed to improve the signs and symptoms of Sweet's syndrome and appeared to be more effective than other drugs we had used. We suggest that further trials of this drug for Sweet's syndrome should be performed.